Biolidics' Covid-19 rapid test kit allowed to be marketed, sold in US
SINGAPORE-BASED cancer diagnostics company Biolidics can now distribute, market and sell its Covid-19 rapid test kits in the US, it said in a bourse filing on Monday.
The Catalist-listed firm completed its listing with the US Food and Drug Administration (FDA) on April 17.
Its test kits are allowed for use by clinical laboratories or healthcare workers for point-of-care testing, but not for home testing.
In its filing, Biolidics said that its test kits are solely used for identifying antibodies to SARS-CoV-2, which is the virus that causes Covid-19.
Its test reports must also state that the tests have not been reviewed by the FDA. A negative result from testing does not rule out a SARS-CoV-2 infection, while a positive result could be due to past or present infections with non-SARS-CoV-2 strains, such as coronavirus HKU1, NL63, OC43, or 229E.
The company's test kits are already allowed for sale in the European Union. It has also received approval for the test kits from Singapore's Health Sciences Authority and the Food and Drug Administration of the Philippines.
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Biolidics shares were flat at 31.5 Singapore cents at Friday's close.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Amazon bets big with CrowdStrike on cybersecurity products
Goldman Sachs scraps EU-era bonus cap for top bankers in UK: source
Thomson Reuters lifts 2024 forecast on first quarter revenue result
DBS customers unable to log into digibank, PayLah! on Thursday
US: Wall St opens higher after Fed leaves interest rates alone
Japan’s Sumitomo Corp net profit down 32% on Madagascar one-off loss